Rehmann Capital Advisory Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$95.6K	Buy	+10,041	New	+$78K	0.01%	667
2025 Q4	–	Sell	-10,141	Closed	-$77K	–	657
2025 Q3	$77K	Hold	10,141	–	–	﹤0.01%	630
2025 Q2	$90.9K	Sell	10,141 -1,375	-12%	-$12.8K	0.01%	604
2025 Q1	$86.4K	Hold	11,516	–	–	0.01%	598
2024 Q4	$86.6K	Sell	11,516 -450	-4%	-$3.42K	0.01%	593
2024 Q3	$90.9K	Sell	11,966 -33	-0.3%	-$251	0.01%	589
2024 Q2	$74.2K	Sell	11,999 -75	-0.6%	-$414	0.01%	572
2024 Q1	$61.3K	Hold	12,074	–	–	﹤0.01%	569
2023 Q4	$72.3K	Sell	12,074 -67	-0.6%	-$388	0.01%	548
2023 Q3	$86K	Hold	12,141	–	–	0.01%	509
2023 Q2	$85.5K	Hold	12,141	–	–	0.01%	530
2023 Q1	$101K	Hold	12,141	–	–	0.01%	526
2022 Q4	$139K	Hold	12,141	–	–	0.01%	528
2022 Q3	$153K	Hold	12,141	–	–	0.02%	499
2022 Q2	$128K	Hold	12,141	–	–	0.01%	481
2022 Q1	$197K	Hold	12,141	–	–	0.02%	508
2021 Q4	$168K	Buy	+12,141	New	+$161K	0.02%	532

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Rehmann Capital Advisory Group's BCRX Position: Q1 2026 in Review

Rehmann Capital Advisory Group opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 10,041 shares worth $95.6K. The stake represents 0.01% of the portfolio and ranks #667 among its holdings. This is a return to the name: Rehmann Capital Advisory Group previously reported a position in BCRX as recently as Q3 2025.

Rehmann Capital Advisory Group first reported a position in BCRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $197K in Q1 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Rehmann Capital Advisory Group held 10,041 shares of BioCryst Pharmaceuticals worth $95.6K as of Q1 2026.
BioCryst Pharmaceuticals was a new Rehmann Capital Advisory Group position in Q1 2026.
BioCryst Pharmaceuticals made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #667 holding.
Rehmann Capital Advisory Group first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
Rehmann Capital Advisory Group's BioCryst Pharmaceuticals position peaked at $197K in Q1 2022.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.